TVM Capital Life Science invests in transformative life science innovations, leveraging a two-pronged strategy: financing early-stage therapeutics through a partnership with Eli Lilly and investing in differentiated commercial-stage medtech, diagnostics, and digital health products. The firm focuses on AI-driven drug development and building value through close collaboration with portfolio companies to accelerate market adoption of novel therapies and medical products.
Bevorzugte Reifephase für die erste Finanzierung.
Breakthrough therapies, medical products, AI-driven drug development, and disruptive life science innovations
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...